Cost-effectiveness analysis of thrombolytic treatment for stroke

Cerebrovascular Diseases

Volumn 20, Issue 3, 2005, Pages 193-200

  Mar, Javier ^a,c   Begiristain, Jose Maria ^b   Arrazola, Arantza ^b  

^a Hospital Alto Deba   (Spain)

^b Basque Government   (Spain)

^c Hospital 'Alto Deba'   (Spain)

Author keywords

Cost effectiveness analysis; Quality of life; Recombinant tissue plasminogen activator; Stroke; Thrombolysis

Indexed keywords

ALTEPLASE; FIBRINOLYTIC AGENT;

CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; DRUG COST; FEMALE; FIBRINOLYTIC THERAPY; HEALTH SURVEY; HOSPITAL DISCHARGE; HOSPITALIZATION; HUMAN; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MONTE CARLO METHOD; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; REVIEW; STROKE;

CEREBROVASCULAR ACCIDENT; COST-BENEFIT ANALYSIS; EUROPE; FEMALE; FIBRINOLYTIC AGENTS; HEALTH CARE COSTS; HUMANS; MALE; MARKOV CHAINS; MODELS, ECONOMIC; THROMBOLYTIC THERAPY; TISSUE PLASMINOGEN ACTIVATOR;

EID: 24344467365     PISSN: 10159770     EISSN: None     Source Type: Journal    
DOI: 10.1159/000087204     Document Type: Review

References (35)

1. Biller J, Love BB: Nihilism and stroke therapy. Stroke 1991;22:1105-1107.
2. Adams HP, Kassell NF, Mazuz H: The patient with transient ischemic attacks. Is this the time for a new therapeutic approach? Stroke 1984; 15:371-375.
3. Straus SE, Majumdar SR, McAlister FA: New evidence for stroke prevention: scientific review. JAMA 2002;288:1388-1395.
4. Goldberg G, Berger GG: Secondary prevention in stroke: a primary rehabilitation concern. Arch Phys Med Rehabil 1988;69:32-40.
5. Fibrinolytic Therapy Trialists' (FTT) Collaborative Group: Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1,000 patients. Lancet 1994;343:311-322.
6. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group: Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995;333:1581-1587.
7. Brott T, Bogousslavsky J: Drug therapy: treatment of acute ischemic stroke. N Engl J Med 2000;343:710-722.
8. Kwiatkowski TG, Libman RB, Frankel M, Tilley BC, Morgenstern LB, Lu M, Broderick JP, Lewandowski CA, Marler JR, Levine SR, Brott T: Effects of tissue plasminogen activator for acute ischemic stroke at one year. N Engl J Med 1999;340:1781-1787.
9. Laupacis A, Feeny D, Detsky AS, Tugwell PX: How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluation. CMAJ 1992;146:473-481.
10. Gold MR, Siegel JE, Russell LB, Weinstein MC: Cost-Effectiveness in Health and Medicine. New York, Oxford University Press, 1996.
11. Alonso I, Regidor E, Rodriguez C, Gutierrez-Fisac JL: Principales causas de muerte en España. 1992. Med Clin (Barc) 1996;107:441-444.
12. Adams HP, Brott TG, Crowell RM, Furlan AJ, Gomez CR, Grotta J, Helgason CM, Marier JR, Woolson RF, Zivin JA, et al: Guidelines for the management of patients with acute ischemic stroke: a statement for healthcare professionals from a special writing group of the Stroke Council, American Heart Association. Circulation 1994;90:1588-1601.
13. American Heart Association: Heart Disease and Stroke Statistics - 2004 Update. Dallas, American Heart Association, 2003.
14. Fagan SC, Morgenstern LB, Pettita A, Ward RE, Tilley BC, Marier JR, Levine SR, Kwiatkowski TG, Frankel M, Brott TG, Walker MD: Cost-effectiveness of tissue plasminogen activator for acute ischemic stroke. Neurology 1998;50:883-890.
15. Sinclair SE, Frighetto L, Loewen PS, Sunderji R, Teal P, Fagan SC, Maria CA: Cost-utility analysis of tissue plasminogen activator therapy for acute ischaemic stroke. A Canadian healthcare perspective. Pharmacoeconomics 2001;19:927-936.
16. Sonnenberg FA, Beck R: Markov models in medical decision making: a practical guide. Med Decis Making 1993;13:322-338.
17. Hankey GJ, Warlow CP: Treatment and secondary prevention of stroke: evidence, costs, and effects on individual and populations. Lancet 1999;354:1457-1463.
18. Bonita R, Solomon N, Broad JB: Prevalence of stroke and stroke-related disability: estimates from the Auckland Stroke Studies. Stroke 1997;28:1898-1902.
19. Mahoney FI, Barthel DW: Functional evaluation: the Barthel index. Md State Med J 1965;14:61-65.
20. Diputación foral de Gipuzkoa, Departamento de Servicios Sociales. Orden foral 809/97. Boletín oficial de Gipuzkoa, 2 de enero de 1998.
21. EuroQoL Group: EuroQoL - A new facility for measurement of health-related quality of life. Health Policy 1990;16:199-208.
22. Badía X, Roset M, Montserrat S, Herdman M, Segura A: La versión española del EuroQoL: descripción y aplicaciones. Med Clin (Barc) 1999;112(suppl 1):S79-S86.
23. O'Brien BJ, Drummond MF, Labelle RJ, Willan A: In search of power and significance: issues in the design and analysis of stochastic cost-effectiveness studies in health care. Med Care 1994;32:150-163.
24. Briggs AH, Goeree R, Blackhouse G, O'Brien B: Probabilistic analysis of cost-effectiveness models: choosing between treatment strategies for gastroesophageal reflux disease. Med Decis Making 2002;22:290-308.
25. Claxton K, Neumann PJ, Araki S, Weinstein MC: Bayesian value-of-information analysis: an application to a policy model of Alzheimer's disease. Int J Technol Assess Health Care 2001;17:38-55.
26. National Institute for Clinical Excellence: Guide to the Methods of Technology Appraisal. London. National Institute for Clinical Excellence, 2004.
27. Altman DG: Practical Statistics for Medical Research. London, Chapman & Hall, 1991.
28. Sacristan JA, Oliva J, del Llano J, Prieto L, Pinto JL: ¿Qué es una tecnología sanitaria eficiente en España? Gac Sanit 2002;4:334-343.
29. Mark DH: Visualizing cost-effectiveness analysis (editorial). JAMA 2002;287:2428-2429.
30. Chapman RH, Stone PW, Sandberg EA, Bell C, Newmann PJ: A comprehensive league table of cost-utility ratios and a sub-table of 'panel-worthy' studies. Med Decis Making 2000;20:451-467.
31. Bosworth HB: Health-related quality of life after stroke: a comprehensive review (editorial). Stroke 2001;32:972.
32. Tengs TO, Yu M, Luistro E: Health-related quality of life after stroke: a comprehensive review. Stroke 2001;32:964-971.
33. Sneew KCA, Aaronson NK, de Haan RJ, Limburg M: Assessing quality of life after stroke: the value and limitations of proxy ratings. Stroke 1997;28:1541-1549.
34. Hackett ML, Duncan JR, Anderson CS, Broad J, Bonita R: Health-related quality of life among long-term survivors of stroke: results from the Auckland Stroke Study, 1991-1992. Stroke 2000;31:440-447.
35. Rothwell PM: The high cost of not funding stroke research: a comparison with heart disease and cancer. Lancet 2001;357:1612-1616.